Kaoru Yamashita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kaoru Yamashita has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Morimoto
Department of Medicine, Tokyo Women’s Medical University Adachi Medical Center, Tokyo, Japan
8 shared publications - Atsuhiro Ichihara
Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, Tokyo, Japan
7 shared publications - Yasufumi Seki
Division of Hormonal Medicine and Bioregulatory Science, Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan
7 shared publications Noriyoshi Takano
Department of Internal Medicine, Tokyo Women's Medical University , Tokyo, 162-8666 , Japan
6 shared publicationsAtsuhiro Ichihara
Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, Shinjuku 162-8666, Japan
4 shared publications- Kanako Bokuda
Department of Internal Medicine, Tokyo Women's Medical University , Tokyo, 162-8666 , Japan
4 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0396
Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review
Pasireotide, a somatostatin analog with high affinity for somatostatin receptor 5 (SSTR5), is frequently used to treat residual or recurrent pituitary adenomas, but it often induces hyperglycemia by suppressing glucagon-like peptide-1 (GLP-1) secretion. Although GLP-1 receptor agonists (GLP-1RAs) have been reported to be effective for pasireotide-induced hyperglycemia, no established treatment strategy currently exists. The present report describes the first documented use of once-weekly subcutaneous tirzepatide in a patient with pasireotide-induced hyperglycemia that remained inadequately controlled despite oral GLP-1RA therapy. A 48-year-old woman without a history of glucose intolerance was diagnosed with a GH/TSH-producing pituitary adenoma/PitNET. Transsphenoidal surgery was performed, followed by initiation of pasireotide for the residual tumor. Subsequently, the patient developed progressive hyperglycemia, with the hemoglobin A1c (HbA1c) level increasing from 6.5% to 7.7%. Oral sitagliptin and semaglutide were sequentially introduced; however, glycemic control remained suboptimal. Upon switching to once-weekly subcutaneous tirzepatide, the HbA1c level decreased markedly from 7.7% to 6.3%, along with an improvement in random blood glucose levels. In conclusion, once-weekly subcutaneous tirzepatide may be a therapeutic option for selected patients with pasireotide-induced hyperglycemia. However, further studies are needed to determine whether its effects differ from those of intensified GLP-1RA therapy.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0396
Open AccessTirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review
Pasireotide, a somatostatin analog with high affinity for somatostatin receptor 5 (SSTR5), is frequently used to treat residual or recurrent pituitary adenomas, but it often induces hyperglycemia by suppressing glucagon-like peptide-1 (GLP-1) secretion. Although GLP-1 receptor agonists (GLP-1RAs) have been reported to be effective for pasireotide-induced hyperglycemia, no established treatment strategy currently exists. The present report describes the first documented use of once-weekly subcutaneous tirzepatide in a patient with pasireotide-induced hyperglycemia that remained inadequately controlled despite oral GLP-1RA therapy. A 48-year-old woman without a history of glucose intolerance was diagnosed with a GH/TSH-producing pituitary adenoma/PitNET. Transsphenoidal surgery was performed, followed by initiation of pasireotide for the residual tumor. Subsequently, the patient developed progressive hyperglycemia, with the hemoglobin A1c (HbA1c) level increasing from 6.5% to 7.7%. Oral sitagliptin and semaglutide were sequentially introduced; however, glycemic control remained suboptimal. Upon switching to once-weekly subcutaneous tirzepatide, the HbA1c level decreased markedly from 7.7% to 6.3%, along with an improvement in random blood glucose levels. In conclusion, once-weekly subcutaneous tirzepatide may be a therapeutic option for selected patients with pasireotide-induced hyperglycemia. However, further studies are needed to determine whether its effects differ from those of intensified GLP-1RA therapy.
- 31 December 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 262, 109306
Clinical and radiological features of Rathke’s cleft cysts with inflammatory change: Multivariable analysis of 262 surgically treated cases
- 31 December 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 262, 109306
Clinical and radiological features of Rathke’s cleft cysts with inflammatory change: Multivariable analysis of 262 surgically treated cases
- Open Access
- 2 November 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (12) , bvad137
Effect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels
Context GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear. Objective We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels. Methods We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year after the pituitary surgery in patients with nonfunctioning pituitary neuroendocrine tumor or Rathke cleft cyst. Results Among 171 patients, 55 (32%) presented with severe GHD (peak GH response to GH-releasing peptide-2 < 9 ng/mL). Serum hs-CRP levels were significantly higher in patients with severe GHD than in those without (P < .001) and significantly correlated with the peak GH (r = −0.50, P < .001). Multiple regression analyses showed that the peak GH significantly and negatively predicted hs-CRP levels (β = −0.345; 95% CI, −0.533 to −0.158) and the lowest quartile of the peak GH (<5.04 ng/mL) were significantly associated with increase in hs-CRP levels (exp [β] = 1.840; 95% CI, 1.209 to 2.801), after controlling for other anterior hormones and metabolic parameters. Postoperative change in the peak GH (N = 60) significantly predicted change in hs-CRP levels (β = −0.391; 95% CI, −0.675 to −0.108), independent of alterations in other anterior hormones and metabolic parameters. Conclusion The inverse association between GH secretion and hs-CRP levels highlights the protective role of GH in the increase in hs-CRP.
- 2 November 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (12) , bvad137
Open AccessEffect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels
Context GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear. Objective We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels. Methods We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year after the pituitary surgery in patients with nonfunctioning pituitary neuroendocrine tumor or Rathke cleft cyst. Results Among 171 patients, 55 (32%) presented with severe GHD (peak GH response to GH-releasing peptide-2 < 9 ng/mL). Serum hs-CRP levels were significantly higher in patients with severe GHD than in those without (P < .001) and significantly correlated with the peak GH (r = −0.50, P < .001). Multiple regression analyses showed that the peak GH significantly and negatively predicted hs-CRP levels (β = −0.345; 95% CI, −0.533 to −0.158) and the lowest quartile of the peak GH (<5.04 ng/mL) were significantly associated with increase in hs-CRP levels (exp [β] = 1.840; 95% CI, 1.209 to 2.801), after controlling for other anterior hormones and metabolic parameters. Postoperative change in the peak GH (N = 60) significantly predicted change in hs-CRP levels (β = −0.391; 95% CI, −0.675 to −0.108), independent of alterations in other anterior hormones and metabolic parameters. Conclusion The inverse association between GH secretion and hs-CRP levels highlights the protective role of GH in the increase in hs-CRP.
- Open Access
- 20 October 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 688-700
Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
Introduction: Renin-angiotensin system inhibitors have been reported to exert protective effects against organ damage and failure; however, the impact of the direct renin inhibitor as monotherapy has not been assessed. Here, we investigated the effects of 24-week monotherapy with aliskiren compared to amlodipine in hypertensive patients with type 2 diabetes or obesity. Methods: In this randomized intervention study, 62 adult hypertensive patients with visceral obesity (defined as a body mass index [BMI] greater than 25 kg/m2 and a visceral adipose tissue area [VFA] greater than 100 cm2) or type 2 diabetes mellitus (age 57 ± 13, 65% men, BMI 28.8 ± 4.8 kg/m2, VFA 134.8 ± 47.0 cm2, blood pressure 141 ± 16/86 ± 13 mm Hg) were randomized to receive 24-week treatment with aliskiren (max. 300 mg) or amlodipine (max. 10 mg). The primary outcome was the change in VFA at 24 weeks post-treatment. Results: Change in VFA did not differ significantly from baseline in either group. Systolic blood pressure significantly decreased at 12 weeks (−10 mm Hg, p = 0.001) and 24 weeks (−10 mm Hg, p = 0.001) in the amlodipine group and at 24 weeks (−11 mm Hg, p = 0.001) in the aliskiren group. Diastolic blood pressure significantly decreased at 24 weeks (−6 mm Hg, p = 0.009) only in the amlodipine group. Although the estimated glomerular filtration rates did not significantly change in either group, the logarithm of urinary albumin excretion significantly decreased at 24 weeks only in the aliskiren group (−0.60, p < 0.001). The 24-week changes in the urinary albumin excretion significantly correlated with the changes in the plasma renin activity in the aliskiren group (r = 0.51, p = 0.008). Conclusion: Aliskiren monotherapy did not show any superiority to amlodipine monotherapy on VFA, estimated glomerular filtration rates, or urinary albumin excretion in obese or type 2 diabetic hypertensive patients.
- 20 October 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 688-700
Open AccessEffects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
Introduction: Renin-angiotensin system inhibitors have been reported to exert protective effects against organ damage and failure; however, the impact of the direct renin inhibitor as monotherapy has not been assessed. Here, we investigated the effects of 24-week monotherapy with aliskiren compared to amlodipine in hypertensive patients with type 2 diabetes or obesity. Methods: In this randomized intervention study, 62 adult hypertensive patients with visceral obesity (defined as a body mass index [BMI] greater than 25 kg/m2 and a visceral adipose tissue area [VFA] greater than 100 cm2) or type 2 diabetes mellitus (age 57 ± 13, 65% men, BMI 28.8 ± 4.8 kg/m2, VFA 134.8 ± 47.0 cm2, blood pressure 141 ± 16/86 ± 13 mm Hg) were randomized to receive 24-week treatment with aliskiren (max. 300 mg) or amlodipine (max. 10 mg). The primary outcome was the change in VFA at 24 weeks post-treatment. Results: Change in VFA did not differ significantly from baseline in either group. Systolic blood pressure significantly decreased at 12 weeks (−10 mm Hg, p = 0.001) and 24 weeks (−10 mm Hg, p = 0.001) in the amlodipine group and at 24 weeks (−11 mm Hg, p = 0.001) in the aliskiren group. Diastolic blood pressure significantly decreased at 24 weeks (−6 mm Hg, p = 0.009) only in the amlodipine group. Although the estimated glomerular filtration rates did not significantly change in either group, the logarithm of urinary albumin excretion significantly decreased at 24 weeks only in the aliskiren group (−0.60, p < 0.001). The 24-week changes in the urinary albumin excretion significantly correlated with the changes in the plasma renin activity in the aliskiren group (r = 0.51, p = 0.008). Conclusion: Aliskiren monotherapy did not show any superiority to amlodipine monotherapy on VFA, estimated glomerular filtration rates, or urinary albumin excretion in obese or type 2 diabetic hypertensive patients.
- Open Access
- 5 October 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (Supplement)
THU069 Growth Hormone Secretion And Serum High-sensitivity C-reactive Protein Levels In Adult Patients With Non-functioning Pituitary Tumors
Disclosure: Y. Seki: None. S. Morimoto: None. K. Bokuda: None. D. Watanabe: None. S. Watanabe: None. K. Yamashita: None. N. Takano: None. A. Ichihara: None. Background: Growth hormone (GH) deficiency, which causes visceral obesity and non-alcohol fatty liver disease, increases cardiovascular event risks. Serum high-sensitivity C-reactive protein (hs-CRP) levels has been reported to estimate those risks. GH supplementation therapy was reported to decrease the serum hs-CRP levels in GH deficient patients, however, the association between GH secretion and serum hs-CRP levels have been unclear. Patients and Methods: We retrospectively reviewed charts of the patients with non-functioning pituitary adenoma and Rathke’s cysts who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests to assess GH secretion, and investigated the association between GH secretion and background characteristics. Patients who had a history of pituitary surgery, severe renal insufficiency or active inflammatory diseases, or received GH supplementation therapy were excluded. Results: Among 171 patients (100 NFPA and 71 Rathke’s cysts), 55 (32%) presented severe GH deficiency, as diagnosed using GHRP-2 tests. Serum hs-CRP levels were significantly higher in the patients with severe GH deficiency than in those without severe GH deficiency (754 [393—1330] vs 249 [113—537] ng/mL, P < 0.001). Serum hs-CRP levels were significantly correlated with logarithm of peak GH response to GHRP-2 (r = -0.50, P < 0.001), but not with IGF-1 SD score (r = -0.10, P = 0.21). In the multiple regression analysis, peak GH response to GHRP-2 was a significant variable for determining serum hs-CRP levels (β = -0.340, P = 0.001) after adjustment with age, sex, BMI, smoking habit, alcohol consumption, hypertension, diabetes mellitus, dyslipidemia, abnormal liver function, and other pituitary hormone deficiencies. Severe GH deficiency were significantly associated with for serum hs-CRP levels higher than 1000 ng/mL (Odds ratio, 2.58 ;95% Confidence interval 1.15-5.78) when adjusted for obesity and abnormal liver function. Conclusion: GH secretion was significantly and negatively associated with serum hs-CRP levels independent of atherosclerotic risk factors, metabolic complications of GH deficiency, and other anterior pituitary hormone secretions. Presentation: Thursday, June 15, 2023
- 5 October 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (Supplement)
Open AccessTHU069 Growth Hormone Secretion And Serum High-sensitivity C-reactive Protein Levels In Adult Patients With Non-functioning Pituitary Tumors
Disclosure: Y. Seki: None. S. Morimoto: None. K. Bokuda: None. D. Watanabe: None. S. Watanabe: None. K. Yamashita: None. N. Takano: None. A. Ichihara: None. Background: Growth hormone (GH) deficiency, which causes visceral obesity and non-alcohol fatty liver disease, increases cardiovascular event risks. Serum high-sensitivity C-reactive protein (hs-CRP) levels has been reported to estimate those risks. GH supplementation therapy was reported to decrease the serum hs-CRP levels in GH deficient patients, however, the association between GH secretion and serum hs-CRP levels have been unclear. Patients and Methods: We retrospectively reviewed charts of the patients with non-functioning pituitary adenoma and Rathke’s cysts who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests to assess GH secretion, and investigated the association between GH secretion and background characteristics. Patients who had a history of pituitary surgery, severe renal insufficiency or active inflammatory diseases, or received GH supplementation therapy were excluded. Results: Among 171 patients (100 NFPA and 71 Rathke’s cysts), 55 (32%) presented severe GH deficiency, as diagnosed using GHRP-2 tests. Serum hs-CRP levels were significantly higher in the patients with severe GH deficiency than in those without severe GH deficiency (754 [393—1330] vs 249 [113—537] ng/mL, P < 0.001). Serum hs-CRP levels were significantly correlated with logarithm of peak GH response to GHRP-2 (r = -0.50, P < 0.001), but not with IGF-1 SD score (r = -0.10, P = 0.21). In the multiple regression analysis, peak GH response to GHRP-2 was a significant variable for determining serum hs-CRP levels (β = -0.340, P = 0.001) after adjustment with age, sex, BMI, smoking habit, alcohol consumption, hypertension, diabetes mellitus, dyslipidemia, abnormal liver function, and other pituitary hormone deficiencies. Severe GH deficiency were significantly associated with for serum hs-CRP levels higher than 1000 ng/mL (Odds ratio, 2.58 ;95% Confidence interval 1.15-5.78) when adjusted for obesity and abnormal liver function. Conclusion: GH secretion was significantly and negatively associated with serum hs-CRP levels independent of atherosclerotic risk factors, metabolic complications of GH deficiency, and other anterior pituitary hormone secretions. Presentation: Thursday, June 15, 2023
- 2 May 2023
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 90
A negative association between growth hormone secretion and inflammation in adult patients with non-functioning pituitary mass
Background: Growth hormone (GH) deficiency, which causes visceral obesity and non-alcohol fatty liver disease, increases cardiovascular event risks. High-sensitivity C-reactive protein (hs-CRP), an inflammatory marker associated with increased cardiovascular risk, reportedly decreased after GH supplementation in GH-deficient patients, however, the association between GH secretion and inflammation remains unclear. Patients and Methods: We retrospectively investigated the association between GH secretion assessed using a GH-releasing peptide-2 (GHRP-2) test and serum hs-CRP level in the patients with non-functioning pituitary neuroendocrine tumor (NF-PitNET) and Rathke’s cleft cyst (RCC). Patients with severe renal insufficiency, active inflammatory and malignant diseases, and a history of pituitary surgery, and under GH supplementation therapy were excluded. Results: Among 171 patients (100 NF-PitNET and 71 RCC), 55 (32%) presented severe GHD. Serum hs-CRP levels were significantly higher in the patients with severe GHD than those without (754 [393-1330] vs 249 [113-537] ng/ml, P r=-0.50, P 1000 ng/ml) (adjusted odds ratio, 2.55; 95% confidence interval 1.15-5.70). In the 60 patients who received pituitary surgeries, the postoperative changes in peak GH response to GHRP-2 (β = -0.320, P = 0.025) significantly estimated those in serum hs-CRP levels independent of other anterior hormone secretions. Conclusions: The negative association between GH secretion and serum hs-CRP levels suggested an important role of impaired GH secretion in the increased cardiovascular risks through the development of inflammation.
- 2 May 2023
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 90
A negative association between growth hormone secretion and inflammation in adult patients with non-functioning pituitary mass
Background: Growth hormone (GH) deficiency, which causes visceral obesity and non-alcohol fatty liver disease, increases cardiovascular event risks. High-sensitivity C-reactive protein (hs-CRP), an inflammatory marker associated with increased cardiovascular risk, reportedly decreased after GH supplementation in GH-deficient patients, however, the association between GH secretion and inflammation remains unclear. Patients and Methods: We retrospectively investigated the association between GH secretion assessed using a GH-releasing peptide-2 (GHRP-2) test and serum hs-CRP level in the patients with non-functioning pituitary neuroendocrine tumor (NF-PitNET) and Rathke’s cleft cyst (RCC). Patients with severe renal insufficiency, active inflammatory and malignant diseases, and a history of pituitary surgery, and under GH supplementation therapy were excluded. Results: Among 171 patients (100 NF-PitNET and 71 RCC), 55 (32%) presented severe GHD. Serum hs-CRP levels were significantly higher in the patients with severe GHD than those without (754 [393-1330] vs 249 [113-537] ng/ml, P r=-0.50, P 1000 ng/ml) (adjusted odds ratio, 2.55; 95% confidence interval 1.15-5.70). In the 60 patients who received pituitary surgeries, the postoperative changes in peak GH response to GHRP-2 (β = -0.320, P = 0.025) significantly estimated those in serum hs-CRP levels independent of other anterior hormone secretions. Conclusions: The negative association between GH secretion and serum hs-CRP levels suggested an important role of impaired GH secretion in the increased cardiovascular risks through the development of inflammation.
- Open Access
- 6 March 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (5) , bvab039
Transient Leukopenia After Radioactive Iodine Treatment in Patients With Graves’ Disease: A Retrospective Cohort Study
Context Radioactive 131I (RAI) for the treatment of differentiated thyroid cancer is known to induce bone marrow suppression, which occurs approximately 1 month after treatment. However, it is unknown whether RAI therapy for Graves’ disease causes bone marrow suppression. Objective This study aimed to evaluate the short- and long-term effects of RAI therapy on bone marrow function in patients with Graves’ disease. Methods In this retrospective cohort study, we included patients with Graves’ disease who received RAI therapy only once between 2003 and 2019 at Tokyo Women’s Medical University. Blood cell counts at baseline were compared with counts at 1, 2, 4, 12, 24, 48, 144, and 240 weeks after RAI therapy. Moreover, changes in white blood cell (WBC) count and leukopenia at 1 week after RAI treatment were compared by baseline patient characteristics. Results We enrolled 48 patients. Leukopenia was observed in 6 patients at 1 week after RAI treatment, and the overall WBC count significantly decreased (P < 0.001) 1 week after the therapy; however, the values were not significantly lower after 2 weeks. Neither red blood cell nor platelet count were significantly altered. Moreover, independent of other factors, the neutrophil count at the baseline was significantly negatively associated with changes in WBC count or the occurrence of leukopenia 1 week after the RAI treatment. Conclusion These data showed that RAI treatment induced transient reduction in the WBC count 1 week after treatment, although WBC levels were subsequently restored.
- 6 March 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (5) , bvab039
Open AccessTransient Leukopenia After Radioactive Iodine Treatment in Patients With Graves’ Disease: A Retrospective Cohort Study
Context Radioactive 131I (RAI) for the treatment of differentiated thyroid cancer is known to induce bone marrow suppression, which occurs approximately 1 month after treatment. However, it is unknown whether RAI therapy for Graves’ disease causes bone marrow suppression. Objective This study aimed to evaluate the short- and long-term effects of RAI therapy on bone marrow function in patients with Graves’ disease. Methods In this retrospective cohort study, we included patients with Graves’ disease who received RAI therapy only once between 2003 and 2019 at Tokyo Women’s Medical University. Blood cell counts at baseline were compared with counts at 1, 2, 4, 12, 24, 48, 144, and 240 weeks after RAI therapy. Moreover, changes in white blood cell (WBC) count and leukopenia at 1 week after RAI treatment were compared by baseline patient characteristics. Results We enrolled 48 patients. Leukopenia was observed in 6 patients at 1 week after RAI treatment, and the overall WBC count significantly decreased (P < 0.001) 1 week after the therapy; however, the values were not significantly lower after 2 weeks. Neither red blood cell nor platelet count were significantly altered. Moreover, independent of other factors, the neutrophil count at the baseline was significantly negatively associated with changes in WBC count or the occurrence of leukopenia 1 week after the RAI treatment. Conclusion These data showed that RAI treatment induced transient reduction in the WBC count 1 week after treatment, although WBC levels were subsequently restored.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
1983-P: Dihomo-Gamma-Linolenic Acid and Estimated Delta-5-Desaturase Activity Are Associated with Obesity and Metabolic Components in Type 2 Diabetic Patients
Polyunsaturated fatty acid (PUFA) is an essential class of dietary fatty acids, because of the lack of endogenous enzymes for desaturation in humans. Previous research on n-3 PUFA has demonstrated several health benefits and antiatherogenic actions, but n-6 PUFA have not received much research attention. We investigated whether serum fatty acid composition, especially n-6 PUFAs and desaturase activity, is associated with obesity in type 2 diabetic patients. Subjects were 80 type 2 diabetic patients (age: 60.3±13.9 years) who had no EPA agent intake. They were divided into two groups: obese group (n=52) with a BMI more than 25 kg/m2 and non-obese group (n=28) with a BMI less than 25 kg/m2. Fatty acid levels in serum were measured using gas chromatography. The desaturase activity for n-6 PUFAs was calculated as the arachidonic acid/dihomo-gamma-linolenic acid (DGLA) ratio for Δ5 desaturase (D5D). The obese group revealed a higher saturated fatty acid (SFA) and DGLA levels than those in the non-obese group. No significant difference was observed in the serum n-3 PUFA levels between the two groups. The D5D index of the obese group was significantly lower than that of the non-obese group. Serum DGLA levels showed significant positive correlations with waist circumference, BMI, triglyceride, and hepatic AST and ALT levels. Moreover, SFA showed a significant positive correlation with BMI. The levels of D5D index showed a significant negative correlation with BMI. Increase in serum DGLA levels was related to the number of metabolic factors. These results suggest that type 2 diabetic patients with obesity had changes in their blood fatty acid profile, especially increased DGLA levels. The high levels of blood DGLA indicate downregulation of n-6 metabolism, probably caused by the decreased activity of D5D. The fat quality in the diet and changes in desaturase activity might contribute to the development of obesity. Disclosure M. Saito: None. M. Higa: None. T. Suzuki: None. M. Michishita: None. M. Hijikata: None. K. Yamashita: None. K. Ikehara: None. T. Ichijo: None.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
1983-P: Dihomo-Gamma-Linolenic Acid and Estimated Delta-5-Desaturase Activity Are Associated with Obesity and Metabolic Components in Type 2 Diabetic Patients
Polyunsaturated fatty acid (PUFA) is an essential class of dietary fatty acids, because of the lack of endogenous enzymes for desaturation in humans. Previous research on n-3 PUFA has demonstrated several health benefits and antiatherogenic actions, but n-6 PUFA have not received much research attention. We investigated whether serum fatty acid composition, especially n-6 PUFAs and desaturase activity, is associated with obesity in type 2 diabetic patients. Subjects were 80 type 2 diabetic patients (age: 60.3±13.9 years) who had no EPA agent intake. They were divided into two groups: obese group (n=52) with a BMI more than 25 kg/m2 and non-obese group (n=28) with a BMI less than 25 kg/m2. Fatty acid levels in serum were measured using gas chromatography. The desaturase activity for n-6 PUFAs was calculated as the arachidonic acid/dihomo-gamma-linolenic acid (DGLA) ratio for Δ5 desaturase (D5D). The obese group revealed a higher saturated fatty acid (SFA) and DGLA levels than those in the non-obese group. No significant difference was observed in the serum n-3 PUFA levels between the two groups. The D5D index of the obese group was significantly lower than that of the non-obese group. Serum DGLA levels showed significant positive correlations with waist circumference, BMI, triglyceride, and hepatic AST and ALT levels. Moreover, SFA showed a significant positive correlation with BMI. The levels of D5D index showed a significant negative correlation with BMI. Increase in serum DGLA levels was related to the number of metabolic factors. These results suggest that type 2 diabetic patients with obesity had changes in their blood fatty acid profile, especially increased DGLA levels. The high levels of blood DGLA indicate downregulation of n-6 metabolism, probably caused by the decreased activity of D5D. The fat quality in the diet and changes in desaturase activity might contribute to the development of obesity. Disclosure M. Saito: None. M. Higa: None. T. Suzuki: None. M. Michishita: None. M. Hijikata: None. K. Yamashita: None. K. Ikehara: None. T. Ichijo: None.
- Open Access
- 1 March 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 524 (1) , 184-189
Adrenal cortex hypoxia modulates aldosterone production in heart failure
- 1 March 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 524 (1) , 184-189
Open AccessAdrenal cortex hypoxia modulates aldosterone production in heart failure
- Open Access
- 1 January 2020
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 9 (1) , 43-51
Effect of High β-glucan Barley on Postprandial Blood Glucose and Insulin Levels in Type 2 Diabetic Patients
Fuse Y, et al. Clin Nutr Res. 2020 Jan;9(1):43-51. https://doi.org/10.7762/cnr.2020.9.1.43
- 1 January 2020
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 9 (1) , 43-51
Open AccessEffect of High β-glucan Barley on Postprandial Blood Glucose and Insulin Levels in Type 2 Diabetic Patients
Fuse Y, et al. Clin Nutr Res. 2020 Jan;9(1):43-51. https://doi.org/10.7762/cnr.2020.9.1.43